+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Pediatric Vaccines Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5175922
  • Report
  • August 2020
  • Region: Global
  • 116 Pages
  • Mordor Intelligence


  • AstraZeneca
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus (CSL Limited)
The pediatric vaccine market is expected to register a CAGR of 7% during the forecast period, 2020-2025. The growth of the pediatric vaccines market is attributed to the rising burden of chronic diseases, along with the importance and awareness of immunization, technological advancements in vaccines, and an increase in the government and non-government funding in R&D.
  • As per the World Health Organization (WHO), 2019, new surveillance data reported that the cases of measles and rubella rose by 300% in the first three months of 2019, compared to the same period of 2018. This increase has been observed in two consecutive years, with outbreaks mainly in the Democratic Republic of the Congo, Ethiopia, Georgia, Kazakhstan, Kyrgyzstan, Madagascar, Myanmar, Philippines, Sudan, Thailand, and Ukraine, mostly among the children. Furthermore, between the period of January 1 to July 31, 2019, 182 countries reported 364,808 measles cases to the World Health Organization (WHO), compared to 129,239 measles cases, during the same period in 2018.
  • As immunization plays a significant role in modern medicine, there are several international programs for children, which may vary based on the disease. However, these programs are primarily driving the demand in the pediatric vaccines market.
  • There are many initiatives going on each year across many countries to urge for greater action on immunization. The aim of many organizations active in this healthcare segment is to extend the immunization having present coverage of less than 80% or 60%. As per the 2019 initiative under the Pan American Health Organization (PAHO), about 20 countries planned to vaccinate more than 2.25 million children and adults against measles, through initiatives and innovative awareness programs. In 2017, about 116.2 million children were immunized, which was the highest ever reported, as per the WHO.​This is likely to positively impact the market growth.
  • On the other hand, the high cost of immunization and less access to healthcare in low- and middle-income countries are anticipated to hamper the market growth over the forecast period.

Key Market Trends

The Conjugate Vaccine Segment is Expected to Grow at a Significant Rate

Conjugate vaccines consist of antigens (poly or oligosaccharides) that are chemically attached to the carrier protein. Attaching the saccharides to protein converts polysaccharides to T-dependent antigens, which elicit robust immune responses in infants and adults. These “glycoconjugate” vaccines elicit T-cell help for B-cells that produce IgG antibodies to the conjugated polysaccharide.

The CDC recommends the routine administration of the pneumococcal conjugate vaccine (PCV13 or Prevnar13) for all children below two years of age.​

Furthermore, the rising focus on research, government initiatives on vaccination, and growing awareness, coupled with the companies' efforts in advancing the vaccines, are expected to have a direct correlation with the market growth.​

In May 2017, Pfizer’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) to prevent pneumonia was selected for the immunization program in certain states of India. In the first phase of vaccination it covered around 5.15 million babies. Pfizer Inc. has supplied the vaccine through UNICEF, under the auspices of Gavi.

Moreover, live attenuated vaccines are expected to register significant growth over the forecast period. The major advantage associated with live attenuated vaccine is that only small doses are required and also no boosters needed, owing to the strong immune response triggered by live attenuated vaccines.​​

The North American Region Holds the Largest Market Share and is Projected to Follow the Same Trend over the Forecast Period

The North American pediatric vaccine market is expected to register a significant market share. This is primarily due to the well-established healthcare infrastructure, especially in the United States, and immunization programs. The scheduled children immunization programs under the Centers for Disease Control and Prevention (CDC), high funding, wide commercial availability of vaccines, and the awareness in society regarding vaccines contribute to the sustained growth in the United States.

Considering the factors responsible for the large size of the US pediatric vaccines market, the country witnesses the highest percentage of children getting vaccinations. This is well described with the data provided by the Centers for Disease Control and Prevention (CDC), which states that there are around 83.4% of children who get vaccinated for diphtheria, tetanus, and pertussis.​ Moreover, polio, being one of the important vaccines, is given to almost 92% of the children across the country, whereas MMR and hepatitis B vaccines are received by 91.1% and 90.5% of the children, respectively. Other vaccines, like chickenpox, pneumococcal conjugate vaccine (PCV), and Combined 7-vaccine series, are received by around 90% of the children. ​

The data provided above indicates that there is a high receiving rate for pediatric vaccines in the United States, which is contributing to the market growth. ​

Competitive Landscape

The pediatric vaccines market consists of several major players, including Merck & Co. Inc., Sanofi SA, Pfizer Inc., Sinova, and Pfizer among others. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown


  • AstraZeneca
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus (CSL Limited)

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Chronic Diseases with the Importance and Awareness of Immunization
4.2.2 Technological Advancements in Vaccines
4.2.3 Increase in the Government and Non-government Funding in R&D
4.3 Market Restraints
4.3.1 Cost of Immunization
4.3.2 Low Medical Coverage and Healthcare Services in Low- and Middle-income Countries
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Vaccine Type
5.1.1 Monovalent
5.1.2 Multivalent
5.2 By Technology
5.2.1 Live Attenuated
5.2.2 Inactivated
5.2.3 Toxoid
5.2.4 Conjugate
5.2.5 Other Technologies
5.3 By Application
5.3.1 Pneumococcal Disease
5.3.2 Influenza
5.3.3 Measles, Mumps, and Rubella (MMR)?
5.3.4 Other Applications
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 Indian Immunologicals Limited
6.1.3 AstraZeneca
6.1.4 Merck & Co. Inc.
6.1.5 Mitsubishi Tanabe Pharma Corporation
6.1.6 Pfizer Inc.
6.1.7 Sanofi SA
6.1.8 Seqirus (CSL Limited)
6.1.9 Sinovac Biotech Ltd
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline PLC
  • Indian Immunologicals Limited
  • AstraZeneca
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus (CSL Limited)
  • Sinovac Biotech Ltd
Note: Product cover images may vary from those shown